Under the terms of the agreement, SGX will receive from Roche an upfront payment, research funding, and milestone payments during product development, as well as royalties from product sales.
Stephen Burley, chief scientific officer of SGX, said in a statement that the move was consistent with the company's strategy to use its FAST technology to discover drug candidates for its partners, as well as oncology candidates for SGX to develop.
SGX's FAST technology identifies drug candidates with a fragment-based approach using high-throughput protein crystallography, computational chemistry and parallel synthesis.